The companies agreed to enhance access to technology from DASI, a leader in AI-driven predictive modeling and digital twin ...
Medtronic (NYSE: MDT) today announced the launch of its Stedi extra support guidewire for use with its Evolut TAVR platform.
More and more medical studies show that heart issues in women are not only underdiagnosed but should be treated differently. A study Medtronic designed to test its Evolut TAVR (transcatheter aortic ...
In patients with symptomatic severe aortic stenosis at intermediate or higher surgical risk, CoreValve or Evolut transcatheter aortic valve implantation (TAVI) was associated with a lower 5-year ...
The US Food and Drug Administration has expanded its indications for the Evolut family of valves (Medtronic) to include redo TAVI inpatients at high risk for surgery. The approval now includes use for ...
Revised Commercial Labeling Broadens Patient Population Who May be Candidates for Transcatheter Aortic Valve Replacement (TAVR) DUBLIN, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the ...
LONDON, England—Ever since the 5-year PARTNER 3 and 4-year EVOLUT Low Risk results were released at TCT 2023, clinicians and researchers—not to mention industry players and ad execs—have been ...
Many believe that transcatheter aortic valve implantation is one of the most exciting and lucrative new technologies to hit the market providing an option for patients to sick to undergo open heart ...
Percutaneous heart valve specialist JenaValve Technology (Munich) just received $10 million in VC funding, supplementing the $62.5 million in funds the company won last year. The cash could help the ...
Abbott ABT recently announced significant progress with Navitor, the company’s latest-generation transcatheter aortic valve implantation (TAVI) system. The company announced late-breaking data for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback